INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 41h ago
House PTR1h ago
SEC 13F1h ago
Robinhood Chain1h ago

Most active filers · 30d

  1. 01FWFogarty Patrick W0B / 206S206 trades$1.10M
  2. 02Kurtz George0B / 202S202 trades$48.06M
  3. 03SPSaba Capital Management, L.P.67B / 19S · 11 late86 trades$21.51M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09SISarowitz Steven I2B / 34S36 trades$21.18M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 179 insiders$893K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLMGNIMAGNITE, INC.Nov 5 – Nov 178 insiders$2.77M
  7. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

73,372 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
24
RE
Reginelli EdwardCFO
BTGOBITGO HOLDINGS, INC.
Option exercise
M—
48.0K sh
Sep 25, 2025Jan 23, 2026
Page 1454 of 1835
← PrevNext →
traded Sep 25, 2025
+120d
SEC Form 4

Evidence

24
PS
Parasuraman SunitaDirector
BTGOBITGO HOLDINGS, INC.
Grant or award
A—
36.0K sh
Sep 6, 2025Jan 23, 2026
traded Sep 6, 2025
+139dSEC Form 4

Evidence

24
HT
Henderson Michael ThomasDirector
SYRESpyre Therapeutics, Inc.
Other acquisition or disposition
J—
63.2K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

24
RE
Reginelli EdwardCFO
BTGOBITGO HOLDINGS, INC.
Option exercise
M—
125.0K sh
Sep 25, 2025Jan 23, 2026
traded Sep 25, 2025
+120dSEC Form 4

Evidence

24
HG
Harrison GilbertDirector
IPARINTERPARFUMS INC
Option exercise
M$93K
1,500 sh
Jan 22, 2026Jan 23, 2026
traded Jan 22, 2026
+1dSEC Form 4

Evidence

23
GC
Gentleman CourtneySee remarks
SYFSynchrony Financial
Tax withholding
F$483K
6,267 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

22
CP
Coyne Terrance P.EVP & CFO
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$2.59M
65.8K sh
Jan 20, 2026Jan 23, 2026
traded Jan 20, 2026
+3dSEC Form 4

Evidence

22
HC
Howse CurtisSee remarks
SYFSynchrony Financial
Tax withholding
F$2.26M
29.3K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

22
BM
Belshe MichaelDirector, CEO, President, CTO, 10% Owner
BTGOBITGO HOLDINGS, INC.
Tax withholding
F$2.30M
127.6K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
TJ
Trahan JeremyGeneral Counsel
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
14.6K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
RP
Radovich PeterPRESIDENT AND COO
MIRMMirum Pharmaceuticals, Inc.
Option exercise
M—
4,167 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
HK
Huffman Patrick KipSVP, Chief Accounting Officer
BHRBBurke & Herbert Financial Services Corp.
Grant or award
A—
950 sh
Jan 22, 2026Jan 23, 2026
traded Jan 22, 2026
+1dSEC Form 4

Evidence

21
CJ
Cambre JeromeVice President of Sales
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
11.7K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
FJ
Fogarty JaneEVP, Legal
CNXCConcentrix Corp
Grant or award
A—
13.9K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
HJ
Howe JolandaSVP, GLOBAL CONTROLLER
MIRMMirum Pharmaceuticals, Inc.
Option exercise
M—
1,542 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
HJ
Howe JolandaSVP, GLOBAL CONTROLLER
MIRMMirum Pharmaceuticals, Inc.
Option exercise
M—
1,542 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
FT
Fitzgerald TraeChief Financial Officer
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
3,329 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
EA
Eidson Charles AndrewDirector, Chief Executive Officer
AMRAlpha Metallurgical Resources, Inc.
Grant or award
A—
8,197 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
MT
Munsey Joshua ToddChief Financial Officer
AMRAlpha Metallurgical Resources, Inc.
Grant or award
A—
2,576 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
HC
Hoyt CaseyDirector, Chief Executive Officer
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
49.6K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
MM
Moore MichaelPresident
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
8,554 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
HV
Hintelmann Robert Victor Jr.Chief Credit Officer
BHRBBurke & Herbert Financial Services Corp.
Grant or award
A—
2,850 sh
Jan 22, 2026Jan 23, 2026
traded Jan 22, 2026
+1dSEC Form 4

Evidence

21
FT
Fitzgerald TraeChief Financial Officer
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
13.3K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
TJ
Thompson Amanda JChief People Officer
GAPGAP INC
Option exercise
M—
20.2K sh
Jan 22, 2026Jan 23, 2026
traded Jan 22, 2026
+1dSEC Form 4

Evidence

21
FS
Francis Andrew ScottDirector, Chief Technology Officer
IDAIT Stamp Inc
Grant or award
A—
50.8K sh
Jan 22, 2026Jan 23, 2026
traded Jan 22, 2026
+1dSEC Form 4

Evidence

21
CJ
Cambre JeromeVice President of Sales
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
2,930 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
MM
Manning MeredithChief Commercial Officer
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
28.6K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
TJ
Trahan JeremyGeneral Counsel
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
14.6K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
RZ
Roberts ZacharyEVP of R&D
ALLOAllogene Therapeutics, Inc.
Open-market sale
SELL$41K
26.3K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
FW
Frazier WilliamDirector, Chief Medical Officer
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
850 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
GN
Genner Gareth NevilleDirector, Chief Executive Officer
IDAIT Stamp Inc
Grant or award
A—
84.5K sh
Jan 22, 2026Jan 23, 2026
traded Jan 22, 2026
+1dSEC Form 4

Evidence

21
MM
Moore MichaelPresident
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
34.2K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
HC
Hoyt CaseyDirector, Chief Executive Officer
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
12.4K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
EM
Erginsoy MaryVP, Chief Accounting Officer
ENPHEnphase Energy, Inc.
Grant or award
A—
10.6K sh
Jan 22, 2026Jan 23, 2026
traded Jan 22, 2026
+1dSEC Form 4

Evidence

21
TJ
Trahan JeremyGeneral Counsel
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
3,662 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
BC
Bass CarlDirector
PLPlanet Labs PBC
Option exercise
M—
19.9K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
HC
Hirano Patricia CSEE REMARKS
SLNOSOLENO THERAPEUTICS INC
Grant or award
A—
10.4K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
QJ
Quan JoanneCHIEF MEDICAL OFFICER
MIRMMirum Pharmaceuticals, Inc.
Option exercise
M—
3,334 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
FW
Frazier WilliamDirector, Chief Medical Officer
VMDVIEMED HEALTHCARE, INC.
Option exercise
M—
3,401 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC Form 4

Evidence

21
MJ
Mcdearman JohnDirector, President & CEO
NONENONEWILSON BANK HOLDING CO
Option exercise
M—
1,500 sh
Jan 23, 2026Jan 23, 2026
traded Jan 23, 2026
+0dSEC Form 4

Evidence